Showing results (61-70 of 432) with videos related to

Sort By:
Pageof 44
Critical Reviews in Oncology/Hematology|December 21, 2025
A daily clinical practice decision-making overview for the present metastatic renal cell carcinoma (mRCC) management landscapeSergio Bracarda, Fabio Calabrò, Ugo De Giorgi, et al.
Critical Reviews in Oncology/Hematology|February 28, 2018
Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectivesClaudio Vernieri, Federico Nichetti, Alessandra Raimondi, et al.
Tumori|February 18, 2015
Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumorsSara Pusceddu, Filippo de Braud, Laura Concas, et al.
ESMO Open|March 25, 2020
Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategiesLaura Cosmai, Camillo Porta, Carmelo Privitera, et al.
Critical Reviews in Oncology/Hematology|October 24, 2024
Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: A narrative review on behalf of the meet-URO GroupEmilio Francesco Giunta, Giandomenico Roviello, Vincenza Conteduca, et al.
Therapeutic Advances in Urology|July 2, 2021
Second-line treatment in renal cell carcinoma: clinical experience and decision makingValentina Guadalupi, Giacomo Cartenì, Roberto Iacovelli, et al.
JAMA Network Open|March 6, 2024
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-AnalysisBrigida Anna Maiorano, Massimo Di Maio, Linda Cerbone, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2020
Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitorsRoberto Iacovelli, Chiara Ciccarese, Emilio Bria, et al.
Tumori|December 7, 2022
BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patientsSebastiano Buti, Francesca Trentini, Pierangela Sepe, et al.
Tumori|May 5, 2020
Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trialCamillo Porta, Elena Verzoni, Silvia Zai, et al.
Pageof 44